The Role of Targeted Agents in the Treatment of Metastatic Breast Cancer.

@article{Bischoff2010TheRO,
  title={The Role of Targeted Agents in the Treatment of Metastatic Breast Cancer.},
  author={Joachim Bischoff and Atanas Ignatov},
  journal={Breast care},
  year={2010},
  volume={5 3},
  pages={134-141}
}
To date, blockade of growth factor receptors is the mainstay of targeted therapy in metastatic breast cancer (mBC). Monoclonal antibodies such as trastuzumab and bevacizumab represent the first generation of molecular-based therapies. Both the HER2 inhibitors and the vascular endothelial growth factor (VEGF) antagonists have shown synergism with a broad spectrum of established cytotoxins, thus being approved for first-line treatment of mBC in combination with taxanes. As a next step, tyrosine… CONTINUE READING